Publication

Improving antibacterial prescribing safety in the management of COPD exacerbations: systematic review of observational and clinical studies on potential drug interactions associated with frequently prescribed antibacterials among COPD patients

Wang, Y., Bahar, M. A., Jansen, A. M. E., Kocks, J. W. H., Alffenaar, J-W. C., Hak, E., Wilffert, B. & Borgsteede, S. D., Oct-2019, In : Journal of Antimicrobial Chemotherapy. 74, 10, p. 2848-2864 17 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Wang, Y., Bahar, M. A., Jansen, A. M. E., Kocks, J. W. H., Alffenaar, J-W. C., Hak, E., Wilffert, B., & Borgsteede, S. D. (2019). Improving antibacterial prescribing safety in the management of COPD exacerbations: systematic review of observational and clinical studies on potential drug interactions associated with frequently prescribed antibacterials among COPD patients. Journal of Antimicrobial Chemotherapy, 74(10), 2848-2864. https://doi.org/10.1093/jac/dkz221

Author

Wang, Yuanyuan ; Bahar, Muh. Akbar ; Jansen, Anouk M. E. ; Kocks, Janwillem W. H. ; Alffenaar, Jan-Willem C. ; Hak, Eelko ; Wilffert, Bob ; Borgsteede, Sander D. / Improving antibacterial prescribing safety in the management of COPD exacerbations : systematic review of observational and clinical studies on potential drug interactions associated with frequently prescribed antibacterials among COPD patients. In: Journal of Antimicrobial Chemotherapy. 2019 ; Vol. 74, No. 10. pp. 2848-2864.

Harvard

Wang, Y, Bahar, MA, Jansen, AME, Kocks, JWH, Alffenaar, J-WC, Hak, E, Wilffert, B & Borgsteede, SD 2019, 'Improving antibacterial prescribing safety in the management of COPD exacerbations: systematic review of observational and clinical studies on potential drug interactions associated with frequently prescribed antibacterials among COPD patients', Journal of Antimicrobial Chemotherapy, vol. 74, no. 10, pp. 2848-2864. https://doi.org/10.1093/jac/dkz221

Standard

Improving antibacterial prescribing safety in the management of COPD exacerbations : systematic review of observational and clinical studies on potential drug interactions associated with frequently prescribed antibacterials among COPD patients. / Wang, Yuanyuan; Bahar, Muh. Akbar; Jansen, Anouk M. E.; Kocks, Janwillem W. H.; Alffenaar, Jan-Willem C.; Hak, Eelko; Wilffert, Bob; Borgsteede, Sander D.

In: Journal of Antimicrobial Chemotherapy, Vol. 74, No. 10, 10.2019, p. 2848-2864.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Wang Y, Bahar MA, Jansen AME, Kocks JWH, Alffenaar J-WC, Hak E et al. Improving antibacterial prescribing safety in the management of COPD exacerbations: systematic review of observational and clinical studies on potential drug interactions associated with frequently prescribed antibacterials among COPD patients. Journal of Antimicrobial Chemotherapy. 2019 Oct;74(10):2848-2864. https://doi.org/10.1093/jac/dkz221


BibTeX

@article{85e20accad424c73878e679e8a8fe8ae,
title = "Improving antibacterial prescribing safety in the management of COPD exacerbations: systematic review of observational and clinical studies on potential drug interactions associated with frequently prescribed antibacterials among COPD patients",
abstract = "BACKGROUND:Guidelines advise the use of antibacterials (ABs) in the management of COPD exacerbations. COPD patients often have multiple comorbidities, such as diabetes mellitus and cardiac diseases, leading to polypharmacy. Consequently, drug-drug interactions (DDIs) may frequently occur, and may cause serious adverse events and treatment failure.OBJECTIVES:(i) To review DDIs related to frequently prescribed ABs among COPD patients from observational and clinical studies. (ii) To improve AB prescribing safety in clinical practice by structuring DDIs according to comorbidities of COPD.METHODS:We conducted a systematic review by searching PubMed and Embase up to 8 February 2018 for clinical trials, cohort and case-control studies reporting DDIs of ABs used for COPD. Study design, subjects, sample size, pharmacological mechanism of DDI and effect of interaction were extracted. We evaluated levels of DDIs and quality of evidence according to established criteria and structured the data by possible comorbidities.RESULTS:In all, 318 articles were eligible for review, describing a wide range of drugs used for comorbidities and their potential DDIs with ABs. DDIs between ABs and co-administered drugs could be subdivided into: (i) co-administered drugs altering the pharmacokinetics of ABs; and (ii) ABs interfering with the pharmacokinetics of co-administered drugs. The DDIs could lead to therapeutic failures or toxicities.CONCLUSIONS:DDIs related to ABs with clinical significance may involve a wide range of indicated drugs to treat comorbidities in COPD. The evidence presented can support (computer-supported) decision-making by health practitioners when prescribing ABs during COPD exacerbations in the case of co-medication.",
keywords = "chronic obstructive pulmonary disease, drug interactions, anti-bacterial agents, safety, acute exacerbation",
author = "Yuanyuan Wang and Bahar, {Muh. Akbar} and Jansen, {Anouk M. E.} and Kocks, {Janwillem W. H.} and Alffenaar, {Jan-Willem C.} and Eelko Hak and Bob Wilffert and Borgsteede, {Sander D.}",
year = "2019",
month = oct,
doi = "10.1093/jac/dkz221",
language = "English",
volume = "74",
pages = "2848--2864",
journal = "Journal of Antimicrobial Chemotherapy",
issn = "0305-7453",
publisher = "Oxford University Press",
number = "10",

}

RIS

TY - JOUR

T1 - Improving antibacterial prescribing safety in the management of COPD exacerbations

T2 - systematic review of observational and clinical studies on potential drug interactions associated with frequently prescribed antibacterials among COPD patients

AU - Wang, Yuanyuan

AU - Bahar, Muh. Akbar

AU - Jansen, Anouk M. E.

AU - Kocks, Janwillem W. H.

AU - Alffenaar, Jan-Willem C.

AU - Hak, Eelko

AU - Wilffert, Bob

AU - Borgsteede, Sander D.

PY - 2019/10

Y1 - 2019/10

N2 - BACKGROUND:Guidelines advise the use of antibacterials (ABs) in the management of COPD exacerbations. COPD patients often have multiple comorbidities, such as diabetes mellitus and cardiac diseases, leading to polypharmacy. Consequently, drug-drug interactions (DDIs) may frequently occur, and may cause serious adverse events and treatment failure.OBJECTIVES:(i) To review DDIs related to frequently prescribed ABs among COPD patients from observational and clinical studies. (ii) To improve AB prescribing safety in clinical practice by structuring DDIs according to comorbidities of COPD.METHODS:We conducted a systematic review by searching PubMed and Embase up to 8 February 2018 for clinical trials, cohort and case-control studies reporting DDIs of ABs used for COPD. Study design, subjects, sample size, pharmacological mechanism of DDI and effect of interaction were extracted. We evaluated levels of DDIs and quality of evidence according to established criteria and structured the data by possible comorbidities.RESULTS:In all, 318 articles were eligible for review, describing a wide range of drugs used for comorbidities and their potential DDIs with ABs. DDIs between ABs and co-administered drugs could be subdivided into: (i) co-administered drugs altering the pharmacokinetics of ABs; and (ii) ABs interfering with the pharmacokinetics of co-administered drugs. The DDIs could lead to therapeutic failures or toxicities.CONCLUSIONS:DDIs related to ABs with clinical significance may involve a wide range of indicated drugs to treat comorbidities in COPD. The evidence presented can support (computer-supported) decision-making by health practitioners when prescribing ABs during COPD exacerbations in the case of co-medication.

AB - BACKGROUND:Guidelines advise the use of antibacterials (ABs) in the management of COPD exacerbations. COPD patients often have multiple comorbidities, such as diabetes mellitus and cardiac diseases, leading to polypharmacy. Consequently, drug-drug interactions (DDIs) may frequently occur, and may cause serious adverse events and treatment failure.OBJECTIVES:(i) To review DDIs related to frequently prescribed ABs among COPD patients from observational and clinical studies. (ii) To improve AB prescribing safety in clinical practice by structuring DDIs according to comorbidities of COPD.METHODS:We conducted a systematic review by searching PubMed and Embase up to 8 February 2018 for clinical trials, cohort and case-control studies reporting DDIs of ABs used for COPD. Study design, subjects, sample size, pharmacological mechanism of DDI and effect of interaction were extracted. We evaluated levels of DDIs and quality of evidence according to established criteria and structured the data by possible comorbidities.RESULTS:In all, 318 articles were eligible for review, describing a wide range of drugs used for comorbidities and their potential DDIs with ABs. DDIs between ABs and co-administered drugs could be subdivided into: (i) co-administered drugs altering the pharmacokinetics of ABs; and (ii) ABs interfering with the pharmacokinetics of co-administered drugs. The DDIs could lead to therapeutic failures or toxicities.CONCLUSIONS:DDIs related to ABs with clinical significance may involve a wide range of indicated drugs to treat comorbidities in COPD. The evidence presented can support (computer-supported) decision-making by health practitioners when prescribing ABs during COPD exacerbations in the case of co-medication.

KW - chronic obstructive pulmonary disease

KW - drug interactions

KW - anti-bacterial agents

KW - safety

KW - acute exacerbation

U2 - 10.1093/jac/dkz221

DO - 10.1093/jac/dkz221

M3 - Article

VL - 74

SP - 2848

EP - 2864

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

SN - 0305-7453

IS - 10

ER -

ID: 84477080